This pharma stock engaged in radiopharmaceuticals, allergy immunotherapy, contract manufacturing, and drug discovery services, in focus after announcing plans to double its revenue growth from 6,703 Cr to Rs. 13,500 Cr by the financial year 2030.
Stock Price Movement:
With a market capitalization of Rs. 15,062.42 crores, the share of Jubilant Pharmova Limited has reached an intraday high of Rs. 946.45 per equity share, rising nearly around 0.90 percent from its previous day’s close price of Rs. 938. Since then, the stock has retreated and is currently trading at Rs. 945.65 per equity share.
What Happened:
Jubilant Pharmova aims to double its revenue to Rs. 13,500 Cr by FY30, up from Rs. 6,703 Cr in FY24. The company targets an EBITDA margin expansion from 15 percent to 23-25 percent, alongside achieving a zero net debt position from the current Rs. 2,457 Cr.
Additionally, it seeks to improve its RoCE to high teens from the high single digits. This ambitious growth strategy reflects Jubilant Pharmova’s commitment to financial strength, operational efficiency, and long-term value creation, positioning itself for sustainable growth in the pharmaceutical sector.
Partnership:
Jubilant Biosys, via its subsidiary JBIRSPL, has partnered with Pierre Fabre to acquire an 80 percent stake in Jasmin, a French R&D firm. This collaboration strengthens Jubilant’s presence in Europe, enhancing its focus on biologics, antibody therapies, and drug discovery services.
New product launches:
The company aims to launch six to eight products each year across the US and international markets. It has 33 ANDAs awaiting approval in the US, with three already approved in FY25. Additionally, it is increasing exports to the US from its Roorkee facility and has begun supplying products through contract manufacturing partners.
Future Outlook:
The company intends to invest USD 50 million to expand its network to nine sites, securing long-term contracts with leading manufacturers. The radio pharmacies are set to become operational by FY28, expected to drive substantial revenue and profitability, with a projected RoCE exceeding 20 percent.
Product Pipeline:
The company boasts a robust product pipeline in both the SPECT and PET categories, targeting an addressable market of approximately USD 50 million and USD 500 million, respectively, in the medium term. Additionally, in the therapeutic segment, the company is focusing on the development of MIBG.
Recent quarter results:
Jubilant Pharmova Limited’s revenue has increased from Rs. 1,677 crore in Q3 FY24 to Rs. 1,822 crore in Q3 FY25, which has grown by 8.65 percent. The net profit has also grown by 53.03 percent from Rs. 66 crore in Q3 FY24 to Rs. 101 crore in Q3 FY25.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
